Kornimate/medical-research-clean huggingface dataset:
multicenter prospective cohort study of twin maternal-child dyads in china

Conditions: Twin Pregnancy, Antepartum Condition or Complication; Twin to Twin Transfusion as Antepartum Condition; Pre-Term; Pre-Eclampsia; Twin Monochorionic Diamniotic Placenta; Twin Dichorionic Diamniotic Placenta; High Risk Pregnancy; Twin Placenta

Summary: multicenter prospective cohort study of twin maternal-child dyads in china (chitwimc) is supported by national key research and development program of china - reproductive health and women's and children's health protection project. this project is funded by the ministry of science and technology of china under grant number 2023yfc2705900. the chitwimc cohort is led by professor wei yuan from the department of gynecology and obstetrics at peking university third hospital.

the chitwimc cohort focusing on the serious complications of twin pregnancy, establish a multicenter large prospective mother-child cohort of twin pregnancy covering pregnancy→neonatal period→early childhood, and a multi-variety, multi-stage biobank for the study of adverse outcomes of twin pregnancy. the chitwimc cohort is planning to recruit 2000 pregnant women aged 18-45 years from 9 large obstetrical center of major university-affiliated hospitals across china, between december 2023 and may 2026. all women will be enrolled prior to 14 wks of gestation, pregnancy was followed up at 22-28 wks, 30-38 wks of gestation, delivery, postpartum 42 days, 6 months, 12 months. data including demographics, medical history, reproductive history, clinical diagnosis, treatment information, and pregnancy and birth outcomes will be collected via electronic data capture system. track the outcome of severe maternal-fetal complications and early neonatal outcomes of twins, and collect biological samples, including peripheral venous blood, hair and cervicovaginal secretions from pregnant women, placenta tissue, amniotic fluid and unbilical cord blood at delivery, meconium and hair from newborns, buccal mucosa from infants and peripheral venous blood from the husband.

Eligibility criteria:
inclusion criteria: * twin pregnancies * female aged between 18-45 years * gestational age is less than 14 weeks * planning to receive prenatal healthcare and delivery service at the study hospital * signing informed concent and willing to participate exclusion criteria: * women with mental disorders or serious maternal illness that is not eligible to participate * inability to provide informed consent * pregnant women not registered in our hospital
phaco-trabeculotomy vs phaco-trabeculectomy

Conditions: Ophthalmopathy; Glaucoma; Glaucoma, Angle-Closure

Summary: a prospective, randomized comparative study on adult patients with synechial angle closure glaucoma.

patients were randomized into two groups: group a : patients will undergo two site phacoemulfication combined with trabeculectomy group b with phacoemulsification combined with ab-externo trabeculotomy. preoperative assessments including full ophthalmic examination, anterior segment optical coherence tomography (oct) of the angle , endothelial cell count , visual fiend perimetry and biometry. patients were followed up: first day, first week and every two months for 6 month. we will compare adverse effects and outcomes in both groups.

Eligibility criteria:
inclusion criteria: patients with chronic angle closure glaucoma, with or without peripheral anterior synechiae, age more than 18 exclusion criteria: * patient unable for follow up * patients with corneal or retinal disease that affects visual outcome of surgery * patients with previous glaucoma procedure in the eye of study
structural cartography of the insula in temporal epilepsy patients

Conditions: Epilepsy, Temporal Lobe; MRI Scans

Summary: the purpose of this study is to investigate insula structural connectivity in temporal epilepsy patients. insula being at the interface of frontal, parietal, occipital and temporal lobes, its structural organization reflects the brain function. we hypothetize that insular structural organization will be different according to the different subtypes of temporal epilepsy.

the purpose of this study is to investigate insula structural connectivity in temporal epilepsy patients. insula being at the interface of frontal, parietal, occipital and temporal lobes, its structural organization reflects the brain function. we hypothetize that insular structural organization will be different according to the different subtypes of temporal epilepsy.

Eligibility criteria:
inclusion criteria: * epileptic patients: temporal epilepsy or temporal plus epilepsy (temporomesial epilepsy, basal temporal epilepsy, mesio lateral or lateral epilepsy, temporo insular epilepsy, operculo insular epilepsy) * patients who underwent video eeg monitoring with recorded seizures (at least one) * patients who underwent a brain mri with dti sequence before epilepsy surgery * patients who did not refuse the use of their clinical and mri data for this study exclusion criteria: * patients younger than 15 years old * patients with previous brain surgery (before mri) * uncompleted mri sequences (dti, t1 anatomical)

Keywords: structural connectivity insula temporal lobe epilepsy
active somatosensory exercise for chronic stroke

Conditions: Stroke

Summary: the current work aims to examine whether the proposed rehabilitation training or exercise will eventually yield improvements in both motor and somatosensory aspects at one goal. here, the word 'somatosensory' refers to bodily sensations associated with proprioception or kinesthesia, not the sensation of touch, pain, and temperature. the study focuses on upper limb retraining for community-dwelling stroke survivors using a robotic device. at the end of training, both movement accuracy and somatosensory acuity in chronic stroke survivors are presumed to improve, and such paradigm is expected to provide reliable benefits as compared to conventional intervention alone.

long-term disability is common sequela among people with stroke. on top of motor impairment, many stroke survivors suffer from somatosensory impairment of their paretic arm, leading to their inability to perform activities of daily living using upper limb. in this respect, recent research on motor recovery following stroke has begun to place more emphasis on the inclusion of somatosensory retraining in stroke rehabilitation program. although evidence is still scarce, training paradigms that simultaneously combine both somatosensory and motor aspects are considered useful for motor recovery in stroke survivors. principally, studies focusing on such form of training paradigm sought to employ robotic technologies to assist in the retraining of both motor and somatosensory function in stroke survivors. robotic technologies have gained popularity recently for assessing somatosensory function in clinical setting due to its objective quantification of patients' performance and high inter-rater reliability. thus, with the purpose of improving both motor and somatosensory functions in chronic stroke survivors, this proposed study will provide an intensive robotic-based behavioral training intervention to chronic stroke survivors from the community. the intervention will require active participation of the patients through an exploratory strategy.

Eligibility criteria:
inclusion criteria: * first-time ischemic or haemorrhagic stroke survivors; * patients of at least 6-month post-stroke; * patients with severe to moderate sensory impairment as assessed by erasmus nottingham sensory assessment (≤ 6/8); * patients with arm motor impairment, shoulder abduction and elbow extension medical research council (mrc) motor power grade 3-5; exclusion criteria: * patients with bilateral impairment; * patients with high upper-limb spasticity (ashworth scale \> 2); * patients with unilateral neglect as assessed by star cancellation test (score \< 44); * patients with cognitive impairment as assessed by a 2-step instructions from the modified mini mental state examination; * patients with a known history of mental disorders; * patients with the inability to perform upper arm activity due to excessive pain

Keywords: somatosensory proprioception kinesthesia rehabilitation robotics positive reinforcement upper limb retraining
the presence of friends increases food intake in youth

Conditions: Total Caloric Intake; Nutrient Dense Caloric Intake; Energy Dense Caloric Intake

Summary: participants will be matched with either their friend or an unfamiliar peer who is the same gender and about the same age. participants will have 45 minutes of free-play in an experimental room where they will have free access to energy-dense and nutrient-dense foods and an assortment of games and puzzles. the investigators predict that participants eating with a friend will eat significantly more than participants eating with an unfamiliar peer. the investigators also predict that overweight participants eating with an overweight partner will eat significantly more than participants eating with a non overweight participant.


Eligibility criteria:
inclusion criteria: * boys and girls ages 9-15 * between 15th and 95th bmi percentile for their age exclusion criteria: * sickness, psychopathology or developmental disabilities * participant has a cold or upper respiratory distress * food allergies to the study food * participant is on medication or has a medical condition that could influence taste, appetite or olfactory sensory responsiveness.

Keywords: social influence friends eating behavior childhood overweight
po pain management with extended-release dinalbuphine sebacate in patients undergoing arthroscopic shoulder surgery

Conditions: Anesthesiology; Orthopedic

Summary: postoperative pain is common, and the pain intensity can be moderate to severe depending on the site of surgery during the first few days after surgery, and an estimated 15% to 45% experience chronic postsurgical pain. when poorly controlled, the pain can have a significant effect on patient recovery. proper management of postoperative pain is needed to relieve suffering and lead to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction. the currently proposed clinical use of dinalbuphine sebacate is to administer a single dose of naldebain® intramuscularly approximately 12 to 24 hours prior to the planned surgery for pain relief. several clinical studies of naldebain® have been published, such as the use in laparotomy and laparoscopic cholecystectomy. however, toward the arthroscopic shoulder surgery, no article or report has been available publicly yet. the primary objective of this study is to determine the safety and efficacy of single doses of intramuscular naldebain® on patients scheduled to undergo arthroscopic shoulder surgery.

this is a randomized, double-blind, placebo controlled study. patients scheduled to undergo arthroscopic shoulder surgery will be invited to participate in this study. after obtaining the written informed consent, each subject should be sequentially assigned an individual screening number instead of his/her name, chart number or identification. subjects will be randomized to two groups, ds group and control group. both groups should be treated with both routine analgesic regimen and a dose of investigational product. random numbers and assignment treatment were generated by computer program before this study initiated. statistical analyses should be performed on the data to compare the two groups. numerical variables will be present with mean and standard deviation and categorical variables will be present with number and percentage.

Eligibility criteria:
inclusion criteria: 1. scheduled to undergo arthroscopic shoulder surgery. 2. american society of anesthesiology physical class 1-3. 3. ability and willingness to provide informed consent. exclusion criteria: 1. not willing to adhere to the study visit schedule. 2. with a history of hypersensitivity or allergy to opioids, nsaids or sesame oil. 3. with a medical history that may predispose them to abnormal intracranial pressure. 4. any history of narcotic dependency, addiction, or withdrawal. 5. any clinically significant condition that may interfere with study assessments. 6. pregnant or breastfeeding. 7. nonregular sinus cardiac rhythm or implanted pacemakers. 8. prescribed antimuscarinic agents, α2-adrenergic agonists, β1-adrenergic antagonists, or antiarrhythmic agents.

Keywords: analgesia acute postoperative pain arthroscopic shoulder surgery randomized controlled study (rct) dinalbuphine sebacate naldebain
troponin i and t and adverse outcomes in patients with and without diabetes mellitus after coronary intervention

Conditions: Coronary Artery Disease; Diabetes Mellitus

Summary: elevated levels of troponin are associated with future mace. data on the prognostic value of high sensitive troponin t (hs-tnt) as compared to high sensitive troponin i (hs-tni) in diabetic and non-diabetic patients are sparse. we aimed to assess the risk for mace according to gender and diabetes status and to compare the prognostic value of hs-tnt and hs-tni with regards to clinical outcomes in diabetic and non-diabetic patients undergoing percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * percutaneous coronary intervention exclusion criteria: * unsuccessful percutaneous coronary intervention
stopper china:with tandem microspheres in the treatment of localized hepatocellular carcinoma

Conditions: Localized Hepatocellular Carcinoma

Summary: a single-arm trial of transcatheter arterial chemoembolization with tandem microspheres in the treatment of localized hepatocellular carcinoma

it is a prospective, single-arm, multicenter study. the primary effectiveness endpoint for this clinical trial is 6-month overall objective tumor response (orr).

Eligibility criteria:
inclusion criteria: 1. subject is able to provide informed consent and must sign the institutional review board/ethics committee (irb/ec) approved informed consent form. 2. male or female of age ≥18 and ≤75 years. 3. confirmed diagnosis of hcc according to the diagnostic criteria included in the management guideline issued by china's ministry of health in 2017. 4. hcc is diagnosed for the first time or recurrence of tumor after surgical or ablation treatment. 5. single tumor less than 7cm in diameter or multiple tumors with maximum 3 lesions with \>1cm in diameter, individual diameter \<7cm and less than 10cm in total diameter. 6. no previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy) for hcc 7. preserved liver function (child-pugh a or b7). 8. ecog performance status 0 or 1. exclusion criteria: 1. presence of vascular invasion or extra-hepatic spread of disease, or diffuse hcc, defined as \>50% liver involvement , or arteriovenuous fistula 2. macrovascular invasion of main or primary branches of portal vein at entry into the study 3. any contraindication for tace treatment 4. any contraindication for epirubicin administration 5. advanced liver disease (bilirubin levels \>2 mg/dl, ast or alt \>5 times upper limit of normal) 6. renal failure or insufficient renal function (creatinine levels \>2 mg/dl) 7. subject unable to receive mri examination 8. pregnant or breast feeding woman, or plan to become pregnant during treatment or within 12 months of treatment 9. couldn't commit reliable birth control measures during treatment or within 12 months of treatment 10. subject is participating other investigational drug or device clinical trial within 30 days of signing the informed consent 11. subject is not suitable to participate in the study as judged by investigator
safety, pharmacokinetics and pharmacodynamics of two idegasp (one explorative) preparations and two insulin degludec (one explorative) preparations in japanese subjects

Conditions: Diabetes; Healthy

Summary: this trial is conducted in asia. the aim of this trial is to assess the safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of two insulin degludec/insulin aspart (idegasp) preparations and two insulin degludec (insulin 454) preparations in healthy japanese male subjects. idegasp 45 (b) and insulin degludec (b) are explorative formulations, not similar to the proposed commercial formulations.


Eligibility criteria:
inclusion criteria: * healthy japanese male subjects * body mass index (bmi) between 18.0 and 27.0 kg/m\^2 (both inclusive) * body weight above or equal to 50 kg exclusion criteria: * the receipt of any investigational drug within 16 weeks prior to this trial (the planned first dosing) * any clinical laboratory values deviated from the reference range at the laboratory (except for cases within physiological change) or any abnormal electrocardiogram (ecg) findings at the screening, as judged by the investigator or sub-investigator * known or suspected allergy to trial product(s) or related products
mrsa in a trauma population: does decolonization prevent infection?

Conditions: MRSA Colonization

Summary: all trauma patients admitted to certain intensive care units (icu) will have methicillin-resistant staphylococcus aureus (mrsa) nasal swabs performed to determine mrsa colonization status. only those patients who are determined to be colonized with mrsa at admission will be included in the study. all patients must be age 18 and older, admitted directly to the icu from either the emergency department or the operating room with trauma-related injuries, and must not have active or recent known history of mrsa infections. once patients have been determined to be colonized with mrsa, they will be randomized to receive "decolonization" treatment or placebo. "decolonization" treatment will include chlorhexidine baths and mupirocin ointment to both nares for 5 days and placebo will entail "routine" soap baths and lubricating jelly. both groups will be kept on standard contact precautions throughout the course of the study. repeat nasal swabs will be performed at the completion of the treatment regimen to determine the efficacy. patients will be screened for invasive mrsa infections as dictated by their clinical course. the primary outcome measure will be invasive mrsa infection rate (pneumonia, urinary tract infection, bacteremia and soft tissue infection). secondary endpoints include hospital lengths of stay, icu lengths of stay, mechanical ventilatory support requirements, colonization status at the end of treatment, and death rates. as determined by our power analysis, we aim to enroll 75 patients in each arm over the course of 12-24 months.

partway through the enrollment period, it was determined that in the best interests of the patients, the protocol would be altered to eliminate the randomization process and treat all patients with the decolonization treatment regimen.

Eligibility criteria:
inclusion criteria: * colonized with mrsa at admission * age of 18 years or older * admitted directly to the icu from either the ed or the or with trauma-related injuries exclusion criteria: * active or recent known history of mrsa infection * previous institutionalization

Keywords: mrsa decolonization mrsa subtyping mrsa infection rates
single dose and 34-day tolerance study of ingap peptide in insulin deficient patients

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular ingap peptide given for the first time in humans as a potential treatment for diabetes.


Eligibility criteria:
inclusion criteria: patients meeting all of the following inclusion criteria at screening can be considered for admission to the study. stage 1 and stage 2: 1. male and female patients with, type 1 diabetes mellitus that are 18 through 70 years of age, or type 2 diabetes mellitus that are 30 through 70 years of age. 2. patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes mellitus, and are currently well managed with insulin, with or without metformin. 3. patients who have been on stable doses of insulin treatment for 90 days prior to study randomization. exclusion criteria: patients meeting any of the following exclusion criteria at screening will not be enrolled in the study: 1. patients with a history of any clinically significant retinopathy, symptomatic autonomic neuropathy, unstable angina, or kidney problems. 2. patients with an uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure, angina, or peripheral vascular disease. 3. patients who have received any investigational product within 30 days of admission into the study. 4. patients with a history or clinical evidence of multiple organ autoimmune disorders. 5. patients with a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up. 6. patients who are lactating and breastfeeding.
non-responsive diabetic macular edema and spironolactone

Conditions: Diabetic Maculopathy

Summary: diabetic patients with macular edema and choroidal hyperpermeability (as manifested as a thick choroid on oct (optical coherence tomography) and icg hyperfluorescence on icg) unresponsive to anti-vegf (vascular endothelial growth factor) and steroid injections will be treated with spironolactone in addition to the continued treatment of anti-vegf injections, specifically aflibercept (eylea).

this is a non-randomized, prospective study of 10 patients referred during the years 2018 to 2020 with the diagnosis of diabetic macular edema. each patient was noted to have pachychoroid, choroidal hyperpermeability, and most important resistant to multiple anti-vegf and steroid intravitreal injections, and have moderate vision loss. in addition, despite the fact that we use anti-vegf medications, we do not know the levels of vegf in the eye, nor do we have an explanation for the inability to respond to these drugs. this study will determine the degree of vegf concentrations, response to anti-vegf treatments, and determine biomarkers of inflammation as a means for explaining the cause of treatment resistance. subsequently, another pathological process will be treated with spironolactone to see if the degree of contribution of choroidal hyperpermeability to the exudative process.

Eligibility criteria:
inclusion: 1. presence of persistent diabetic cystoid macular edema despite course of anti-vegf injections and intraocular steroids. at the time of study baseline, the patients must be on q4 week intravitreal anti-vegf medications and have failed (poor response - less than 50% decrease in macular central subfield thickness (cst) and volume) with intravitreal steroids (triamcinolone acetonide or dexamethasone implant). 2. evidence of pachychoroid (choroid greater than 300 microns on oct - edi) with pachyvessels on oct or octa. in addition, icg (indocyanine green angiogram) must show evidence of hyperfluorescence. 3. visual acuity of 20/25 to 20/400 at screening and baseline visits using an autorefractor or early treatment diabetic retinopathy study (etdrs). 4. iop ≤ 25 mmhg - patients that screen fail due to elevated iop ˃25 mmhg may rescreen once iop is treated and within normal limits (≤25 mmhg). exclusion: 1. exudative maculopathies due to myopic choroidal degeneration, histoplasmosis, trauma, and specifically, the presence of angioid streaks. 2. myocardial infarction or cerebrovascular accident within the last 6 weeks 3. previous vitrectomy 4. hypokalemia 5. optic neuropathy 6. traction maculopathies 7. allergies to fluorescein and indocyanine, dilating agents, spironolactone, triamcinolone or anti-vegf medications -

Keywords: spironolactone anti-vegf injections aflibercept eylea